UMN Pharma Inc. tag:www.umnpharma.com,2009-03-12:/en//5 2010-06-07T09:29:04Z Movable Type Commercial 4.24-ja UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial tag:www.umnpharma.com,2010:/en//5.144 2010-04-20T09:26:49Z 2010-06-07T09:29:04Z UMN Pharma Inc. today announced Phase II... 管理者 please see here]]> API and UMN Pharma Announce Formulation Process Collaboration tag:www.umnpharma.com,2010:/en//5.143 2010-04-16T09:23:56Z 2010-06-07T09:32:02Z UMN Pharma Inc. and API Co., Ltd. today ... 管理者 please see here]]> IHI Corporation and UMN Pharma Announce Manufacturing Collaboration tag:www.umnpharma.com,2010:/en//5.128 2010-01-26T04:00:00Z 2010-06-07T09:31:30Z IHI Corporation and UMN Pharma today exe... 管理者 please see here]]> UMN Pharma initiates phase II clinical trial for avian influenza A (H5N1) vaccine manufactured from cell-culture, UMN-0501. tag:www.umnpharma.com,2009:/en//5.121 2009-10-05T06:52:51Z 2010-01-26T02:36:02Z UMN Pharma Inc. today announced initiati... 管理者 here.]]> Protein Sciences Corporation signs a contract which amounts to about 147 million dollars with U.S. Department of Health and Human Services for new way to make flu vaccine. tag:www.umnpharma.com,2009:/en//5.109 2009-06-29T10:03:41Z 2009-06-29T10:04:54Z Department of Health and Human Services ... 管理者 →HHS news release]]> UMN Pharma Secures additional investment from IPEC. tag:www.umnpharma.com,2009:/en//5.81 2009-02-16T01:48:54Z 2009-04-10T09:27:16Z UMN Pharma Inc. today announced that it ... 管理者 UMN Pharma Inc. today announced that it has secured an additional investment of roughly $2 million as part of an existing construction agreement with IHI Plant Engineering Corporation (headquartered in Tokyo, hereinafter referred to as "IPEC"), an affiliate of IHI Corporation. The investment was triggered by successful UMN-0501 Phase I/II study results that met certain predetermined criteria. UMN Pharma believes that this funding will serve to further strengthen the collaboration with IPEC. UMN Pharma presents favorable results from Phase I/II study of UMN-0501 at World Health Organization (WHO) pandemic influenza meeting. tag:www.umnpharma.com,2009:/en//5.80 2009-02-13T01:48:19Z 2009-04-10T09:26:50Z UMN Pharma Inc. today announced that Shu... 管理者 UMN Pharma Confirms Immunogenicity and Safety of UMN-0501 Pandemic Influenza Vaccine in Phase I/II Clinical Trials. tag:www.umnpharma.com,2009:/en//5.79 2009-01-15T01:47:02Z 2009-04-10T09:26:08Z Phase I/II clinical trials of UMN-0501, ... 管理者 These results will be released at 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials in February of 2009.

Acrobet PDFNews release PDF file.  (124K)

Get Acrobat reader In order to view this file, you will need to have the following plug-in installed.
]]> Relocation of Tokyo Head Office to Yokohama. Renamed as Yokohama Head Office. tag:www.umnpharma.com,2008:/en//5.78 2008-12-22T01:46:12Z 2009-04-10T09:25:36Z 管理者 UMN-02 pharmacological study results published in the Journal of Pharmacology and Experimental Therapeutics. tag:www.umnpharma.com,2008:/en//5.77 2008-10-01T01:45:10Z 2009-04-14T01:30:37Z UMN-02 pharmacological study results pub... 管理者 the Journal of Pharmacology and Experimental Therapeutics, a leading international academic journal, showed the involvement of 5-HT(2A) receptor activation in choline-deficient, 0.5% D,L-ethionine supplemented (CDE) diet-induced acute pancreatitis in mice. This research paper follows a previous presentation made at the annual Digestive Disease Week (DDW) conference held in May of 2008 in the USA. The data presented at DDW demonstrated the potential efficacy of selective 5-HT(2A) antagonist in acute pancreatitis. The most recent study results showed that UMN-02 ameliorated severe necrotizing acute pancreatitis in mice by inhibiting key inflammatory responses. Based on these experimental results, we believe that UMN-02, a highly specific 5-HT2A antagonist, could serve as a novel therapeutic for the treatment of not only of acute edematous pancreatitis, but also for various symptoms of pancreatitis.
References
Yamaguchi I, Hamada K, Yoshida M, Isayama H, Kanazashi S, and Takeuchi K. Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. J. Pharmacol. Exp. Ther. 2008 Oct. 1;[epub ahead of print].

http://www.ncbi.nlm.nih.gov/pubmed/18832108?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
]]> UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique. tag:www.umnpharma.com,2008:/en//5.76 2008-08-22T01:43:37Z 2009-04-10T09:23:51Z UMN Pharma Inc. announced that it has re... 管理者
Acrobet PDFNews release PDF file.  (108K)

Get Acrobat reader In order to view this file, you will need to have the following plug-in installed.
]]> UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501. tag:www.umnpharma.com,2008:/en//5.75 2008-06-18T01:41:57Z 2009-04-10T09:23:19Z UMN Pharma Inc. today announced initiati... 管理者 UMN Pharma Inc. today announced initiation of phase I/II clinical trials in human subjects with UMN-0501, UMN's pandemic influenza vaccine. In Japan, this is the "first-in-man" clinical study of a pandemic influenza vaccine manufactured by cell-culture. The purpose of this clinical study is to assess safety and efficacy in 125 healthy adults aged 20-40. Study results will be obtained by the end of the year.

Acrobet PDFNews release PDF file.  (39K)

Get Acrobat reader In order to view this file, you will need to have the following plug-in installed.
]]> UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug. tag:www.umnpharma.com,2008:/en//5.74 2008-06-10T01:40:23Z 2009-04-10T09:22:44Z UMN Pharma Inc. today announced that UMN... 管理者
Acrobet PDFNews release PDF file.  (72K)

Get Acrobat reader In order to view this file, you will need to have the following plug-in installed.
]]> UMN Pharma presents at DIGESTIVE DESEASE WEEK 2008 in San Diego, California. tag:www.umnpharma.com,2008:/en//5.73 2008-05-19T01:39:17Z 2009-04-13T03:09:45Z Researchers from UMN Pharma Inc. present... 管理者 Researchers from UMN Pharma Inc. presented pharmacological study results at the annual Digestive Disease Week conference demonstrating the impact of UMN-02, a specific 5HT-2A receptor antagonist, on choline-deficient ethionine-supplemented (CDE) diet-induced necrotizing acute pancreatitis in mice. This presentation showed that UMN-02 ameliorated severe necrotizing acute pancreatitis in mice by inhibiting key inflammatory responses. Based on these experimental results, we believe that UMN-02 could serve as a novel therapeutic for the treatment of acute pancreatitis. UMN-02 is a highly specific 5HT-2A receptor antagonist being developed by UMN Pharma Inc. for the treatment of acute pancreatitis. Further details about our presentation can be found in the conference proceedings from the DIGESTIVE DESEASE WEEK 2008. UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine. tag:www.umnpharma.com,2008:/en//5.72 2008-04-30T01:37:47Z 2009-04-10T09:21:35Z This acquisition will allow UMN Pharma t... 管理者
Acrobet PDFNews release PDF file.  (74K)

Get Acrobat reader In order to view this file, you will need to have the following plug-in installed.
]]>